At its annual meeting on June 11, 2026, stockholders approved an amendment to the 2022 Stock Incentive Plan to increase the number of shares available for issuance by 1,500,000. Stockholders also approved the potential future issuance of common stock under an existing equity line with Lincoln Park Capital Fund, LLC. Other approved items included the election of Class III directors Gregory W. Matz and Sabrina Martucci Johnson, the ratification of Haskell & White LLP as the independent auditor for fiscal year 2026, and an advisory vote on executive compensation. The company operates in the biopharmaceutical industry and develops products for women's health.
